Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* metastatic urothelial cancer;~* disease progression during or after 1 prior platinum-based chemotherapy;~* measurable disease;~* HER2 overexpression (IHC \[2+\] or \[3+\]).~Exclusion Criteria:~* concomitant chemotherapy or immunotherapy;~* active or uncontrolled infection;~* solely CNS metastases;~* clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;~* co-existing malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).